Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc-94m Sestamibi PET MDR Imaging
NCT00082368Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2004
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium tc 94m sestamibi in cancer, sponsored by National Cancer Institute. Primary endpoint: Percent Change in Tc-94m Sestamibi Body Weight Standardized Uptake Value (SUV) Maximum in Tumor Tissue Before and After Administration of Tariquidar at 3 days. Started May 2004; status: completed.
02
Drugs
technetium tc 94m sestamibi
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00082368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082368.